These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37285232)

  • 1. Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-risk Prostate Cancer.
    Wysock JS; Rapoport E; Hernandez H; Gogaj R; Lepor H
    J Urol; 2023 Sep; 210(3):454-464. PubMed ID: 37285232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
    J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone.
    Wysock JS; Becher E; Gogaj R; Velazquez N; Lepor H
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):114-119. PubMed ID: 32636487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
    Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
    J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
    Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
    BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
    Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
    Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
    Chuang R; Kinnaird A; Kwan L; Sisk A; Barsa D; Felker E; Delfin M; Marks L
    J Urol; 2020 Nov; 204(5):941-949. PubMed ID: 32985924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
    Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
    J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease.
    Baskin A; Charondo LB; Balakrishnan A; Cowan JE; Cooperberg MR; Carroll PR; Nguyen H; Shinohara K
    Urol Oncol; 2022 Oct; 40(10):451.e15-451.e20. PubMed ID: 35851186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.
    Aminsharifi A; Jibara G; Tsivian E; Tsivian M; Elshafei A; Polascik TJ
    Clin Genitourin Cancer; 2019 Aug; 17(4):e831-e836. PubMed ID: 31213413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.
    Aminsharifi A; Polascik TJ; Tsivian M; Schulman A; Tsivian E; Tay KJ; Elshafei A; Jones JS
    Clin Genitourin Cancer; 2018 Oct; 16(5):e1073-e1076. PubMed ID: 30054221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
    Elshafei A; Tay KJ; Kara O; Malkoc E; Nyame Y; Arora H; Hatem A; Patel SA; Lugnani F; Polascik TJ; Jones JS
    Clin Genitourin Cancer; 2018 Apr; 16(2):e477-e482. PubMed ID: 29174470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
    Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
    J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
    Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
    BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
    Liu YY; Chiang PH
    Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer.
    Siddiqui KM; Billia M; Al-Zahrani A; Williams A; Goodman C; Arifin A; Violette P; Bauman G; Chin JL
    J Urol; 2016 Oct; 196(4):1105-11. PubMed ID: 27157372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Tan WP; Kotamarti S; Chen E; Mahle R; Arcot R; Chang A; Ayala A; Michael Z; Seguier D; Polascik TJ
    Cancer; 2022 Nov; 128(21):3824-3830. PubMed ID: 36107496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage Cryoablation and Robotic Seminal Vesiculectomy: A Novel Salvage Treatment for Locally Recurrent Prostate Cancer.
    Smigelski MB; Wysock J; Taneja SS; Lepor H
    J Endourol; 2023 Aug; 37(8):876-881. PubMed ID: 37300480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.